Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 165

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Shah, Nirali N., Qin, Haiying, Yates, Bonnie, Su, Ling, Shalabi, Haneen, Raffeld, Mark, Ahlman, Mark A., Stetler-Stevenson, Maryalice, Yuan, Constance, Guo, Shuang, Liu, Siyuan, Hughes, Stephen H., Fry, Terry J., Wu, Xiaolin·2019·Blood Advances
DOI 10.1182/bloodadvances.2019000219
Open this paper in CoChat — free account

Abstract

Key Points: Reexpansion of CAR T cells led to further investigations which confirmed the clonal nature of this expansion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000219

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Clinical course. (A) FDG -positron emission tomography (PET) scan demonstrating significant extramedullary disease burden at pretreatment, followed by clinical response at day 1 30, and subsequent full resolution of any PET-avid disease at day 1 90. Subject was MRD 2 in the bone marrow by the day 1 30 evaluation and remained MRD 2 at the subsequent time points. (B) Clinical timeline with relevant laboratory findings. During the initial CRS, patient had a concurrent rise in CRP and ferritin which coincided with the initial WBC peak. During the second expansion phase, the patient remained clinically well without any fevers and had only modest increase in C-reactive protein (CRP) and ferritin, but with an even higher WBC than with the initial expansion. Concurrent table demonstrates the % of T cells which were CAR 1 in the peripheral blood at the various timepoints.
Figure 1 Clinical course. (A) FDG -positron emission tomography (PET) scan demonstrating significant extramedullary disease burden at pretreatment, followed by clinical response at day 1 30, and subsequent full resolution of any PET-avid disease at day 1 90. Subject was MRD 2 in the bone marrow by the day 1 30 evaluation and remained MRD 2 at the subsequent time points. (B) Clinical timeline with relevant laboratory findings. During the initial CRS, patient had a concurrent rise in CRP and ferritin which coincided with the initial WBC peak. During the second expansion phase, the patient remained clinically well without any fevers and had only modest increase in C-reactive protein (CRP) and ferritin, but with an even higher WBC than with the initial expansion. Concurrent table demonstrates the % of T cells which were CAR 1 in the peripheral blood at the various timepoints.CC-BY-NC-ND · From the PDF
Figure 2 Expansion and persistence of CAR T cell with lentivector integrated in the CBL gene. (A) TCR diversity of CAR product before infusion; samples taken from the patient on days 1 51 and 1 53. A major clonotype that was obvious in day 1 51 and became more dominant on day 1 53. (B) Integration site diversity of CAR product before infusion and samples taken from the patient on days 1 51 and 1 53. The top clones at days 1 51 and 1 53 are the same and have same vector integrated in chr11 at position 119143577. (C) Details of the integration in the dominant clone at days 1 51 and 1 53. The lentiviral vector carrying the EF1a -anti-CD22 CAR integrated in the second intron of CBL gene on chr11, in the opposite orientation to the gene. (D) Longitudinal quantification of CAR vector copy numbers and the CBL clone in patient WBCs by ddPCR. The vector copy number (copies per 100 cells) shows 2 phases of expansion of CAR T cells. The first phase peaked at day 1 7 to 1 14 and subsided around day 1 30. The second phase peaked at day 1 53. The clone with the vector inserted into the CBL gene was quantified with ddPCR assay specific for the junction between the vector and host DNA. The clone is detectable, at a low level, from day 1 7 throughout day 1 53. During the second phase of CAR T expansion, the CBL clone became the dominant clone at day 1 53, constituting 46% of total WBCs in the patient and more than one-half of the CAR T cells.
Figure 2 Expansion and persistence of CAR T cell with lentivector integrated in the CBL gene. (A) TCR diversity of CAR product before infusion; samples taken from the patient on days 1 51 and 1 53. A major clonotype that was obvious in day 1 51 and became more dominant on day 1 53. (B) Integration site diversity of CAR product before infusion and samples taken from the patient on days 1 51 and 1 53. The top clones at days 1 51 and 1 53 are the same and have same vector integrated in chr11 at position 119143577. (C) Details of the integration in the dominant clone at days 1 51 and 1 53. The lentiviral vector carrying the EF1a -anti-CD22 CAR integrated in the second intron of CBL gene on chr11, in the opposite orientation to the gene. (D) Longitudinal quantification of CAR vector copy numbers and the CBL clone in patient WBCs by ddPCR. The vector copy number (copies per 100 cells) shows 2 phases of expansion of CAR T cells. The first phase peaked at day 1 7 to 1 14 and subsided around day 1 30. The second phase peaked at day 1 53. The clone with the vector inserted into the CBL gene was quantified with ddPCR assay specific for the junction between the vector and host DNA. The clone is detectable, at a low level, from day 1 7 throughout day 1 53. During the second phase of CAR T expansion, the CBL clone became the dominant clone at day 1 53, constituting 46% of total WBCs in the patient and more than one-half of the CAR T cells.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 165

Metadata

Authors
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., Liu, S., Hughes, S. H., Fry, T. J., & Wu, X.
Affiliations
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD;
  • Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD;
  • Molecular Diagnostics Section, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD;
  • Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD;
  • Flow Cytometry, Department of Pathology, NCI, NIH, Bethesda, MD;
  • HIV Dynamics and Replication Program, NCI, NIH, Frederick, MD;
ORCID
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2019-08-06
Volume
3
Issue
15
Pages
2317-2322
ISSN
  • 2473-9529
  • 2473-9537
DOI
10.1182/bloodadvances.2019000219
Cited by
165
References
32
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000219
The paper
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., Liu, S., Hughes, S. H., Fry, T. J., & Wu, X. (2019). Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.